Puma Biotechnology, Inc.

NasdaqGS:PBYI 株式レポート

時価総額:US$149.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Puma Biotechnology 将来の成長

Future 基準チェック /06

Puma Biotechnologyの収益と利益はそれぞれ年間1.9%と37.8%減少すると予測されていますが、EPS は年間37.4% 減少すると予測されています。

主要情報

-37.8%

収益成長率

-37.4%

EPS成長率

Biotechs 収益成長24.5%
収益成長率-1.9%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日04 Jun 2024

今後の成長に関する最新情報

Recent updates

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Sep 05
Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M

Aug 04

Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

Jun 04
Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

Puma Bio: Still Worthy Of Consideration After Earnings Surprise

Mar 08

業績と収益の成長予測

NasdaqGS:PBYI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20262301643532
12/31/20252251547442
12/31/20242191045242
3/31/2024227153536N/A
12/31/2023236221427N/A
9/30/20232294524N/A
6/30/2023230-21131N/A
3/31/20232355-614N/A
12/31/20222280-23-16N/A
9/30/202221810-29-29N/A
6/30/2022207-34-36-36N/A
3/31/2022201-49-22-22N/A
12/31/2021253-292121N/A
9/30/2021250-482020N/A
6/30/2021255-351212N/A
3/31/2021272-271828N/A
12/31/2020225-60-91N/A
9/30/2020235-56-28N/A
6/30/2020241-42-11-1N/A
3/31/2020224-822727N/A
12/31/2019272-762222N/A
9/30/2019280-952828N/A
6/30/2019287-922828N/A
3/31/2019284-99-35-34N/A
12/31/2018251-114-25-24N/A
9/30/2018202-147-117-67N/A
6/30/2018145-210-165-114N/A
3/31/201894-243-193-143N/A
12/31/201728-292N/A-172N/A
9/30/20176-301N/A-178N/A
6/30/2017N/A-289N/A-158N/A
3/31/2017N/A-278N/A-143N/A
12/31/2016N/A-276N/A-142N/A
9/30/2016N/A-265N/A-134N/A
6/30/2016N/A-260N/A-136N/A
3/31/2016N/A-258N/A-139N/A
12/31/2015N/A-239N/A-154N/A
9/30/2015N/A-225N/A-140N/A
6/30/2015N/A-200N/A-127N/A
3/31/2015N/A-175N/A-110N/A
12/31/2014N/A-142N/A-77N/A
9/30/2014N/A-110N/A-72N/A
6/30/2014N/A-89N/A-60N/A
3/31/2014N/A-63N/A-54N/A
12/31/2013N/A-55N/A-55N/A
9/30/2013N/A-61N/A-66N/A

アナリストによる今後の成長予測

収入対貯蓄率: PBYIの収益は今後 3 年間で減少すると予測されています (年間-37.8% )。

収益対市場: PBYIの収益は今後 3 年間で減少すると予測されています (年間-37.8% )。

高成長収益: PBYIの収益は今後 3 年間で減少すると予測されています。

収益対市場: PBYIの収益は今後 3 年間で減少すると予想されています (年間-1.9% )。

高い収益成長: PBYIの収益は今後 3 年間で減少すると予測されています (年間-1.9% )。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: PBYIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘